Evaluation des effets cardiovasculaires du liraglutide: conception et donnees de base de l'etude Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER®)

Translated title of the contribution: Design of the Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER® trial)

M. Marre, S. P. Marso, N. R. Poulter, S. E. Nissen, M. A. Nauck, B. Zinman, G. H. Daniels, S. Pocock, W. M. Steinberg, R. M. Bergenstal, J. F E Mann, L. Steen Ravn, K. Brown Frandsen, A. C. Moses, J. B. Buse

Research output: Contribution to journalArticle

Abstract

LEADER® (Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcomes results) is a clinical trial evaluating the long-term effect of liraglutide on the incidence of cardiovascular events among 9 340 patients with type 2 diabetes at high cardiovascular risk. The primary endpoint was the occurrence of cardiovascular death, nonfatal myocardial infarction, or stroke. Patients, naive or treated with conventional diabetes therapy, were randomized 1:1 to receive liraglutide or placebo, and followed up to 5 years after randomization. LEADER® design is presented here.

Original languageFrench
Pages (from-to)316-328
Number of pages13
JournalMedecine des Maladies Metaboliques
Volume9
Issue number3
StatePublished - 2015

Fingerprint

Random Allocation
Type 2 Diabetes Mellitus
Stroke
Myocardial Infarction
Placebos
Clinical Trials
Liraglutide
Incidence
Therapeutics

Keywords

  • cardiovascular.
  • GLP-1 receptor agonists
  • Liraglutide
  • type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics
  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

Evaluation des effets cardiovasculaires du liraglutide : conception et donnees de base de l'etude Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER®). / Marre, M.; Marso, S. P.; Poulter, N. R.; Nissen, S. E.; Nauck, M. A.; Zinman, B.; Daniels, G. H.; Pocock, S.; Steinberg, W. M.; Bergenstal, R. M.; Mann, J. F E; Steen Ravn, L.; Brown Frandsen, K.; Moses, A. C.; Buse, J. B.

In: Medecine des Maladies Metaboliques, Vol. 9, No. 3, 2015, p. 316-328.

Research output: Contribution to journalArticle

Marre, M, Marso, SP, Poulter, NR, Nissen, SE, Nauck, MA, Zinman, B, Daniels, GH, Pocock, S, Steinberg, WM, Bergenstal, RM, Mann, JFE, Steen Ravn, L, Brown Frandsen, K, Moses, AC & Buse, JB 2015, 'Evaluation des effets cardiovasculaires du liraglutide: conception et donnees de base de l'etude Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER®)', Medecine des Maladies Metaboliques, vol. 9, no. 3, pp. 316-328.
Marre, M. ; Marso, S. P. ; Poulter, N. R. ; Nissen, S. E. ; Nauck, M. A. ; Zinman, B. ; Daniels, G. H. ; Pocock, S. ; Steinberg, W. M. ; Bergenstal, R. M. ; Mann, J. F E ; Steen Ravn, L. ; Brown Frandsen, K. ; Moses, A. C. ; Buse, J. B. / Evaluation des effets cardiovasculaires du liraglutide : conception et donnees de base de l'etude Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER®). In: Medecine des Maladies Metaboliques. 2015 ; Vol. 9, No. 3. pp. 316-328.
@article{e62c62ae39aa418d96ff75a737921af9,
title = "Evaluation des effets cardiovasculaires du liraglutide: conception et donnees de base de l'etude Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER{\circledR})",
abstract = "LEADER{\circledR} (Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcomes results) is a clinical trial evaluating the long-term effect of liraglutide on the incidence of cardiovascular events among 9 340 patients with type 2 diabetes at high cardiovascular risk. The primary endpoint was the occurrence of cardiovascular death, nonfatal myocardial infarction, or stroke. Patients, naive or treated with conventional diabetes therapy, were randomized 1:1 to receive liraglutide or placebo, and followed up to 5 years after randomization. LEADER{\circledR} design is presented here.",
keywords = "cardiovascular., GLP-1 receptor agonists, Liraglutide, type 2 diabetes",
author = "M. Marre and Marso, {S. P.} and Poulter, {N. R.} and Nissen, {S. E.} and Nauck, {M. A.} and B. Zinman and Daniels, {G. H.} and S. Pocock and Steinberg, {W. M.} and Bergenstal, {R. M.} and Mann, {J. F E} and {Steen Ravn}, L. and {Brown Frandsen}, K. and Moses, {A. C.} and Buse, {J. B.}",
year = "2015",
language = "French",
volume = "9",
pages = "316--328",
journal = "Medecine des Maladies Metaboliques",
issn = "1957-2557",
publisher = "Elsevier Masson",
number = "3",

}

TY - JOUR

T1 - Evaluation des effets cardiovasculaires du liraglutide

T2 - conception et donnees de base de l'etude Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER®)

AU - Marre, M.

AU - Marso, S. P.

AU - Poulter, N. R.

AU - Nissen, S. E.

AU - Nauck, M. A.

AU - Zinman, B.

AU - Daniels, G. H.

AU - Pocock, S.

AU - Steinberg, W. M.

AU - Bergenstal, R. M.

AU - Mann, J. F E

AU - Steen Ravn, L.

AU - Brown Frandsen, K.

AU - Moses, A. C.

AU - Buse, J. B.

PY - 2015

Y1 - 2015

N2 - LEADER® (Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcomes results) is a clinical trial evaluating the long-term effect of liraglutide on the incidence of cardiovascular events among 9 340 patients with type 2 diabetes at high cardiovascular risk. The primary endpoint was the occurrence of cardiovascular death, nonfatal myocardial infarction, or stroke. Patients, naive or treated with conventional diabetes therapy, were randomized 1:1 to receive liraglutide or placebo, and followed up to 5 years after randomization. LEADER® design is presented here.

AB - LEADER® (Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcomes results) is a clinical trial evaluating the long-term effect of liraglutide on the incidence of cardiovascular events among 9 340 patients with type 2 diabetes at high cardiovascular risk. The primary endpoint was the occurrence of cardiovascular death, nonfatal myocardial infarction, or stroke. Patients, naive or treated with conventional diabetes therapy, were randomized 1:1 to receive liraglutide or placebo, and followed up to 5 years after randomization. LEADER® design is presented here.

KW - cardiovascular.

KW - GLP-1 receptor agonists

KW - Liraglutide

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84942887765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942887765&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84942887765

VL - 9

SP - 316

EP - 328

JO - Medecine des Maladies Metaboliques

JF - Medecine des Maladies Metaboliques

SN - 1957-2557

IS - 3

ER -